References
- Carlsson A. Historical perspective of the chemistry and Pharmacological treatment of schizophrenia. Handbook of Schizophrenia, Vol. 2: Neurochemistry and Neuropharmacology of Schizophrenia, F. A. Henn, L. E. DeLisi. Elsevier, Amsterdam 1987; 1–15
- Wong D. F., Wagner H. N., Tune L. E., Dannals R. F., Pearlson G. D., Links J. M., Tamminga C. A., Broussolle E. P., Ravert H. T., Wilson A. A., Toung J. K. T., Malat J., Williams F. A., O'Touma L. A., Snyder S. H., Kuhar M. J., Gjedde A. A. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986; 234: 1558–1563
- Farde L., Wiesel F.-A., Hall H., Halldin C., Stone-Elander S., Sedvall G. No D2 receptor increase in PET study of schizophrenia. Arch. Gen. Psychiatry 1987; 44: 671–672
- Bischoff S., Bittiger H., Krauss J., Vassout A., Waldmeier P. Affinity changes of rat striatal dopamine receptors in vivo after acute bupropion treatment. Eur. J. Pharmacol. 1984; 184: 173–176
- Bischoff S., Krauss J., Grunenwald C., Gunst F., Heinrich M., Schaub M., Stöcklin K., Vassout A., Waldmeier P., Maiˇtre L. Endogenous dopamine (DA) modulates [3H]spiperone binding in vivo in rat brain. J. Receptor Res. 1991; 11: 163–175
- Bischoff S., Baumann P., Krauss J., Maiˇtre L., Vassout A., Storni A., Chouinard G. CGP 25454A, a novel and selective presynaptic dopamine autoreceptor antagonist. Naunyn Schmiedeberg's Arch. Pharmacol. 1994; 350: 230–238
- Vassout A., Bruinink A., Krauss J., Waldmeier P., Bischoff S. Regulation of dopamine receptors by bupropion: comparison with antidepressants and CNS stimulants. J. Receotor Res. 1993; 13: 341–354
- Bischoff S., Bittiger H., Krauss J. In vivo [3H]spiperone binding to the rat hippocampal formation: involvement of dopamine receptors. Eur. J. Pharmacol. 1980; 68: 305–315
- Bischoff S. Towards the understanding of the neuroanatomical substrate of schizophrenia - the contribution of savoxepine. Novel Antipsychotic Drugs, H. Y. Meltzer. Raven Press, NY 1992; 117–134, chap. 12
- Köhler C., Hall H., Ogren S.-O., Gawell L. Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem. Pharmacol. 1985; 34: 2251–2259
- Kuhar M. J., Murrin L. C., Malouf A. T., Klemm N. Dopamine receptor binding in vivo: Feasibility of autoraciographic studies. Life Sci. 1978; 22: 203–210
- Seeman P., Van Tol H. H. M. Dopamine receptor pharmacology. TIPS 1994; 15: 264–270
- Andersen P. H. Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain. Eur. J. Pharmacol. 1988; 146: 113–120
- Inoue O., Kobayashi K., Tsukada H., Itoh T., Langstrom B. Difference in in vivo receptor binding between [3H]N-methylspiperone and [3H]raclopride in reserpine-treated mouse brain. J. Neural Transm. 1991; 85: 1–10
- Baudry M., Martres M.-P., Schwartz J.-C. In vivo binding of 3H-pimozide in mouse striatum: effects of dopamine agonists and antagonists. Life Sci. 1977; 21: 1163–1170
- Köhler C., Hall H., Gawell L. Regional in vivo binding of the substituted benzamide [3H]eticlopride in the rat brain: Evidence for selective labelling of dopamine receptors. Eur. J. Pharmacol. 1986; 120: 217–226
- Sokoloff P., Giros B., Martres M.-P., Bouthenet M.-L., Schwartz J.-C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347: 146–151
- Van Tol H. H. M., Bunzow J. R., Guan H.-C., Sunahara R. K., Seeman P., Niznik H. B., Civelli O. Cloning of the gene for a human D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610–614
- Farde L., Hall H., Pauli S., Halldin C. Variability in D2-dopamine receptor density and affinity: A PET study with [11C]raclopride in man. Synapse 1995; 20: 200–208